Galderma Laboratories, LP, has announced the publication of the long-term efficacy and safety results of a 1-year, open-label, non-comparative study of Mirvaso® (brimonidine) Topical Gel, 0.33% in patients with moderate

This content is restricted to site members. If you are an existing user, please log in. New users may register below.

Existing Users Log In